Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab Tesirine in DLBCL or HGBCL With Hepatic Impairment
NCT05660395Phase 1Terminated
- Sponsor
- ADC Therapeutics
- Start
- Jul 2023
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
Phase 1, open-label trial of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL) and high grade B-cell lymphoma (HGBCL) (3 arms), sponsored by ADC Therapeutics. Primary endpoint: Dose-Limiting Toxicity. Started Jul 2023; status: terminated.
02
Drugs
loncastuximab tesirine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT05660395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660395.